The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
Related to this article
The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.
The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
The oral PLK1 inhibitor onvansertib received FDA orphan drug designation in CMML.
Advertisement
Advertisement
Trending on OncLive
1
Reinforcing Prophylaxis Adherence and Choosing Frontline Therapy
2
Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC
3
Rinatabart Sesutecan for Patients With Platinum-Resistant Ovarian Cancer: First Efficacy and Safety Results From the Phase 2 Cohort of the RAINFOL-01 Study
4
Phase 3 IMpactMF Trial Evaluating Imetelstat in R/R Myelofibrosis Is Discontinued
5